Biograph mct flow pet ct system

All eligible participants underwent ¹⁸F-Florzolotau tau PET imaging and T1-weighted MR imaging within 2 weeks from the baseline visit. The tosylate precursor of the tracer was obtained from APRINOIA Therapeutics (Suzhou, China). Because of its light sensitivity, both manufacturing and injection of ¹⁸F-Florzolotau were carried out under a green light-emitting diode (510 nm) [10 (link)]. ¹⁸F-Florzolotau tau PET imaging was acquired using a 20-min protocol (90 − 110 min) on a Biograph mCT Flow PET/CT system (Siemens Healthcare GmbH, Erlangen, Germany) and reconstructed using a 3D-ordered subset expectation maximization algorithm. T1-weighted MR imaging was acquired using a 3.0-T horizontal magnet (Discovery MR750; GE Medical Systems, Milwaukee, WI, USA). The details for imaging acquisition could be found in the previous publication [11 (link)].

The mean (standard deviation) interval from PET imaging to blood collection was 2.6 (5.0) weeks. PET imaging ATN biomarkers were assessed using the following tracers: ¹⁸F-florbetapir for A (¹⁸F-AV-45; 50 − 70 min post-injection), ¹⁸F-Florzolotau for T (90 − 110 min post-injection), and ¹⁸F-FDG for N (60 − 70 min post-injection). Static images were acquired on different days on a Biograph mCT Flow PET/CT system (Siemens, Erlangen, Germany). High-resolution structural MRI images obtained with a 3.0-T horizontal magnet scanner (Discovery MR750; GE Medical Systems, Milwaukee, WI) were used for spatial normalization. The protocols used for acquisition have been described previously in detail [30 (link)–32 (link)].